Filtered By:
Condition: Multiple Sclerosis
Education: Study
This page shows you your search results in order of date.
Order by Relevance | Date
Total 888 results found since Jan 2013.
The role of the indoles in microbiota-gut-brain axis and potential therapeutic targets: A focus on human neurological and neuropsychiatric diseases
Neuropharmacology. 2023 Aug 22:109690. doi: 10.1016/j.neuropharm.2023.109690. Online ahead of print.ABSTRACTAt present, a large number of relevant studies have suggested that the changes in gut microbiota are related to the course of nervous system diseases, and the microbiota-gut-brain axis is necessary for the proper functioning of the nervous system. Indole and its derivatives, as the products of the gut microbiota metabolism of tryptophan, can be used as ligands to regulate inflammation and autoimmune response in vivo. In recent years, some studies have found that the levels of indole and its derivatives differ signifi...
Source: Neuropharmacology - August 24, 2023 Category: Drugs & Pharmacology Authors: Yi Zhou Yue Chen Hui He Meichang Peng Meiqin Zeng Haitao Sun Source Type: research
Methods to Study Inflammasome Activation in the Central Nervous System: Immunoblotting and Immunohistochemistry
Methods Mol Biol. 2023;2696:223-238. doi: 10.1007/978-1-0716-3350-2_15.ABSTRACTThe inflammasome is a multiprotein complex that is responsible for mounting an innate immune response through the activation of caspase-1 and the cleavage of interleukin-1β. This multiprotein complex plays an important role in a variety of central nervous system (CNS) diseases and conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, and traumatic brain injury, among others. Here we describe methodological procedures to carry out immunoblotting and immunohistochemical techniques used to study inflammasome sign...
Source: Molecular Medicine - August 14, 2023 Category: Molecular Biology Authors: Brianna Cyr Juan Pablo de Rivero Vaccari Source Type: research
Efficacy of rehabilitation interventions evaluated in common neurological conditions in improving participation outcomes: A systematic review
CONCLUSION: There is a limited evidence of the identified rehabilitation interventions to improve participation in common neurological conditions. However, there was a paucity of articles involving individual with Parkinson's disease that met the inclusion criteria.PMID:37501621 | DOI:10.1177/02692155231191383
Source: Clinical Rehabilitation - July 28, 2023 Category: Rehabilitation Authors: Oy éné Kossi Joke Raats Jonas Wellens Mathias Duckaert Stijn De Baets Dominique Van de Velde Peter Feys Source Type: research
Repeatability of quantitative T1rho magnetic resonance imaging in normal brain tissues at 3.0T
T1rho imaging is a quantitative MRI technique based on the properties of spin –lattice relaxation in the rotating frame, otherwise known as T1rho relaxation. The measured signal is obtained by the decay of magnetisation in the transverse plane, in the presence of a spin-lock radiofrequency field. T1rho is sensitive to low frequency interactions, and provides a viable approa ch to assess the macromolecular environment inside tissues. In recent years, quantitative T1rho imaging has been increasingly explored in various neurological conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s Di...
Source: Physica Medica: European Journal of Medical Physics - July 21, 2023 Category: General Medicine Authors: Lei Wang, Weitian Chen, Yurui Qian, Tiffany Y. So Source Type: research
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion
Transl Stroke Res. 2023 Jun 16. doi: 10.1007/s12975-023-01164-2. Online ahead of print.ABSTRACTRepulsive guidance molecule A (RGMa) is an inhibitor of neuronal growth and survival which is upregulated in the damaged central nervous system following acute spinal cord injury (SCI), traumatic brain injury, acute ischemic stroke (AIS), and other neuropathological conditions. Neutralization of RGMa is neuroprotective and promotes neuroplasticity in several preclinical models of neurodegeneration and injury including multiple sclerosis, AIS, and SCI. Given the limitations of current treatments for AIS due to narrow time windows ...
Source: Cell Research - June 16, 2023 Category: Cytology Authors: Peer B Jacobson Andrea Mothe Aharon Levy Michael Krakovsky Bradley A Hooker Xiaomeng Zhang Jennifer Mollon Yulia Mordashova Mathias Droescher Sabine Weiss Stefan Barghorn Ingeborg Dreher Khader Awwad Volker Nimmrich Lili Huang Emma Fung Wayne R Buck Kimbe Source Type: research
Validity, reliability and minimal detectable change of Mini-BESTest Turkish version in neurological disorders
ConclusionsMini-BESTestTR showed significant correlations with other balance assessment measures, and concurrent and convergent validity of Mini-BESTestTR was demonstrated when administered to a sample of patients with chronic stroke, Parkinson ’s disease and multiple sclerosis.
Source: Acta Neurologica Belgica - June 16, 2023 Category: Neurology Source Type: research
Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion
AbstractRepulsive guidance molecule A (RGMa) is an inhibitor of neuronal growth and survival which is upregulated in the damaged central nervous system following acute spinal cord injury (SCI), traumatic brain injury, acute ischemic stroke (AIS), and other neuropathological conditions. Neutralization of RGMa is neuroprotective and promotes neuroplasticity in several preclinical models of neurodegeneration and injury including multiple sclerosis, AIS, and SCI. Given the limitations of current treatments for AIS due to narrow time windows to intervention (TTI), and restrictive patient selection criteria, there is significant...
Source: Translational Stroke Research - June 16, 2023 Category: Neurology Source Type: research
Validity, reliability and minimal detectable change of Mini-BESTest Turkish version in neurological disorders
ConclusionsMini-BESTestTR showed significant correlations with other balance assessment measures, and concurrent and convergent validity of Mini-BESTestTR was demonstrated when administered to a sample of patients with chronic stroke, Parkinson ’s disease and multiple sclerosis.
Source: Acta Neurologica Belgica - June 16, 2023 Category: Neurology Source Type: research
Neuro-Ophthalmic Visual Impairment in the Setting of COVID-19
We describe and elaborate on mechanisms of disease, including para-infectious inflammation, hypercoagulability, endothelial damage, and direct neurotropic viral invasion. Despite global vaccination programs, new variants of COVID-19 continue to pose an international threat, and patients with rare neuro-ophthalmic complications are likely to continue to present for care.Afferent complications from COVID-19 include homonymous visual field loss, with or without higher cortical visual syndromes, resulting from stroke, intracerebral hemorrhage, or posterior reversible leukoencephalopathy. Optic neuritis has frequently been repo...
Source: Seminars in Neurology - June 13, 2023 Category: Neurology Authors: Dinkin, Marc Sathi, Swetha Tags: Review Article Source Type: research
